119 related articles for article (PubMed ID: 1776747)
1. Evaluation of HP 029 (velnacrine maleate) in Alzheimer's disease.
Murphy MF; Hardiman ST; Nash RJ; Huff FJ; Demkovich JJ; Dobson C; Knappe UE
Ann N Y Acad Sci; 1991; 640():253-62. PubMed ID: 1776747
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
3. Velnacrine for Alzheimer's disease.
Birks J; Wilcock GG
Cochrane Database Syst Rev; 2004; (2):CD004748. PubMed ID: 15106259
[TBL] [Abstract][Full Text] [Related]
4. Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
Ann Pharmacother; 1992 Sep; 26(9):1118-22. PubMed ID: 1421679
[TBL] [Abstract][Full Text] [Related]
5. Clinical safety, tolerance, and plasma levels of the oral anticholinesterase 1,2,3,4-tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's disease: preliminary findings.
Cutler NR; Murphy MF; Nash RJ; Prior PL; De Luna DM
J Clin Pharmacol; 1990 Jun; 30(6):556-61. PubMed ID: 2355106
[TBL] [Abstract][Full Text] [Related]
6. Multiple dose pharmacokinetics, safety, and tolerance of velnacrine (HP 029) in healthy elderly subjects: a potential therapeutic agent for Alzheimer's disease.
Puri SK; Ho I; Hsu R; Lassman HB
J Clin Pharmacol; 1990 Oct; 30(10):948-55. PubMed ID: 2229455
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's patients should be included in phase I clinical trials to evaluate compounds for Alzheimer's disease.
Cutler NR; Sramek JJ; Murphy MF; Nash RJ
J Geriatr Psychiatry Neurol; 1992; 5(4):192-4. PubMed ID: 1418362
[TBL] [Abstract][Full Text] [Related]
8. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
Zemlan FP; Keys M; Richter RW; Strub RL
Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
[TBL] [Abstract][Full Text] [Related]
9. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
10. Clinical trials with velnacrine: (PROPP) the physician reference of predicted probabilities--a statistical model for the estimation of hepatotoxicity risk with velnacrine maleate.
Hardiman S; Miller K; Murphy M
Acta Neurol Scand Suppl; 1993; 149():46-52. PubMed ID: 8128839
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment postural blood pressure drop as a possible predictor of response to the cholinesterase inhibitor velnacrine (HP 029) in Alzheimer's disease.
Pomara N; Deptula D; Singh R
Psychopharmacol Bull; 1991; 27(3):301-7. PubMed ID: 1775603
[TBL] [Abstract][Full Text] [Related]
12. The effect of food on the bioavailability of velnacrine (HP 029) in healthy elderly men: a potential Alzheimer agent.
Puri SK; Hsu RS; Ho I; Lassman HB
J Clin Pharmacol; 1989 Oct; 29(10):956-60. PubMed ID: 2592587
[TBL] [Abstract][Full Text] [Related]
13. Side effects of long acting cholinesterase inhibitors.
Beermann B
Acta Neurol Scand Suppl; 1993; 149():53-4. PubMed ID: 8128840
[TBL] [Abstract][Full Text] [Related]
14. Single dose safety, tolerance, and pharmacokinetics of HP 029 in healthy young men: a potential Alzheimer agent.
Puri SK; Hsu RS; Ho I; Lassman HB
J Clin Pharmacol; 1989 Mar; 29(3):278-84. PubMed ID: 2723116
[TBL] [Abstract][Full Text] [Related]
15. Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease.
Ebmeier KP; Hunter R; Curran SM; Dougal NJ; Murray CL; Wyper DJ; Patterson J; Hanson MT; Siegfried K; Goodwin GM
Psychopharmacology (Berl); 1992; 108(1-2):103-9. PubMed ID: 1410128
[TBL] [Abstract][Full Text] [Related]
16. Caregiver time use: an outcome measure in clinical trial research on Alzheimer's disease.
Clipp EC; Moore MJ
Clin Pharmacol Ther; 1995 Aug; 58(2):228-36. PubMed ID: 7648773
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic and early clinical studies with velnacrine.
Siegfried KR
Acta Neurol Scand Suppl; 1993; 149():26-8. PubMed ID: 8128834
[TBL] [Abstract][Full Text] [Related]
18. Effect of glutathione depletion and oxidative stress on the in vitro cytotoxicity of velnacrine maleate.
al Casey S; Brewster D; Viau C; Acosta D
Toxicol Lett; 1995 Apr; 76(3):257-65. PubMed ID: 7762013
[TBL] [Abstract][Full Text] [Related]
19. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
20. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]